Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Non-Squamous Non-Small Cell Lung Cancer: early-phase trial registry
3 of 4 indexed Metastatic Non-Squamous Non-Small Cell Lung Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 3 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Metastatic Non-Squamous Non-Small Cell Lung Cancer: 4 US clinical trials tracked, 3 recruiting.
Metastatic Non-Squamous Non-Small Cell Lung Cancer is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is CatalYm, running 2 of these trials.
Enrollment posture brief
Registry condition metastatic-non-squamous-non-small-cell-lung-cancer
OPEN 3 | RECR 75% | LATE 1 | EARLY 3 | RANK #4115 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)
Metastatic Non-Squamous Non-Small Cell Lung Cancer lists 3 open slots (75% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Non-Squamous Non-Small Cell Lung Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Non-Squamous Non-Small Cell Lung Cancer is recruiting above its size-band peers.
3 of 4 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Genelux Corporation
NCT06463665
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
CatalYm
NCT07246863
Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC
CatalYm
NCT07098988
Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer
Incyte Corporation
NCT04205812
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Non-Squamous Non-Small Cell Lung Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Non-Squamous Non-Small Cell Lung Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Non-Squamous Non-Small Cell Lung Cancer page
4 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Metastatic Non-Squamous Non-Small Cell Lung Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- CatalYm sponsors the most Metastatic Non-Squamous Non-Small Cell Lung Cancer trials on record, review their full trial history before evaluating a specific study. See CatalYm's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Non-Squamous Non-Small Cell Lung Cancer condition card totals 4 registered trials; most-linked intervention Docetaxel; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.